Glucotrack, Inc.
No SEC Form 4 filings for $GCTK in the last 30 days.
See all $GCTK insider activity →Glucotrack (GCTK) shareholders approved new share issuances linked to financing agreements. Proposals 1 and 2, requiring Nasdaq compliance for issuing over 20% of shares, passed with over 84% and 85% 'for' votes, respectively. The company amended warrants to require shareholder approval for future exercises.
Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. As previously disclosed, on August 4, 2026, Glucotrack, Inc. (the “Company”) entered into a securities purchase agreement with an investor (the “PIPE Purchaser”) for a private placement of securities. At the closing, the Comp
GlucoTrack raised $4.5M in cash, with $11.6M in convertible notes. The notes convert at a variable price, and the deal includes warrants for 4.83M shares. The company had $1.124M cash and $7.664M in operating cash use in the last six months, raising concerns about its liquidity.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning GCTK (Glucotrack, Inc.). Coverage has skewed bearish: 0 bullish, 2 neutral, and 3 bearish.
Recent GCTK coverage spans corporate actions and mergers & acquisitions.
Dilution from approved share issuances may pressure the stock lower in the short term.
Dilution from approved share issuances may pressure the stock price in the short term.
GlucoTrack raised $4.5M in cash, with $11.6M in convertible notes. The notes convert at a variable price, and the deal includes warrants for 4.83M shares. The company had $1.124M cash and $7.664M in operating cash use in the last six months, raising concerns about its liquidity.
New capital may support R&D and extend runway, but conversion price $3.12 could dilute shareholders if notes convert.
The financing provides cash and extends existing debt, potentially supporting near‑term operations and share price.
AlphAI scores every news story that mentions GCTK with an AI model for sentiment and relevance, and aggregates insider trades from Glucotrack, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Glucotrack (GCTK) shareholders approved new share issuances linked to financing agreements. Proposals 1 and 2, requiring Nasdaq compliance for issuing over 20% of shares, passed with over 84% and 85% 'for' votes, respectively. The company amended warrants to require shareholder approval for future exercises.
2 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. As previously disclosed, on August 4, 2026, Glucotrack, Inc. (the “Company”) entered into a securities purchase agreement with an investor (the “PIPE Purchaser”) for a private placement of securities. At the closing, the Comp
1 min readGlucoTrack raised $4.5M in cash, with $11.6M in convertible notes. The notes convert at a variable price, and the deal includes warrants for 4.83M shares. The company had $1.124M cash and $7.664M in operating cash use in the last six months, raising concerns about its liquidity.
2 min readGlucotrack, Inc. (NASDAQ: GCTK) announced a $11.5 million convertible note financing on September 11, 2026. The deal includes $4.5 million in new cash and $4.5 million in rolled-over notes. The notes have an initial conversion price of $3.12 per share, and warrants are exercisable at $7.50 per share. The financing aims to support the company's development of an implantable blood glucose monitoring system.
1 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Glucotrack Announces $11.5 Million Financing RUTHERFORD, N.J., and LA JOLLA, Calif., September 11, 2026 – Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced definitive agreements for convertible notes with an aggregate principal amount of
1 min readGlucotrack (GCTK) raised $11.5M via convertible notes with a $3.12 conversion price and warrants at $7.50. The funds support diabetes tech development. Shares fell 25% to $2.43. The company completed a 1-for-15 reverse split on August 31, 2026.
2 min readGlucotrack (GCTK) settled a $10.9M indebtedness dispute with Alto, paying $2M in cash and issuing a $2M 5% convertible note due by Aug. 31, 2027, convertible at $2.98 per share. The agreement includes legal fee coverage and mutual releases upon full payment.
1 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into a Material Definitive Agreement. On September 4, 2026, Glucotrack, Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B (“Alto”), Erik Emerson,
2 min readGlucoTrack (GCTK) executed a 1-for-15 reverse stock split, reducing outstanding shares from 11.97 million to 798,144. The split, approved by shareholders, took effect on Aug. 28, 2026, and will be reflected in trading from Aug. 31, 2026. The company's par value and authorized shares remain unchanged.
1 min readGlucotrack (GCTK) filed an amendment to its Form 8-K, adding financial statements and pro forma results related to its merger with Lokahi Therapeutics. The filing includes unaudited and audited financials of Lokahi, as well as pro forma combined financials of the merged entity. This update is part of the reverse merger transaction previously reported by Glucotrack.
1 min read
